Skip to main content

Table 3 Subgroup analysis

From: Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry

  Gp 1 IPAH n = 28 Gp 1 PAH-CTD n = 39 Gp 2 PH-LHD n = 21 Gp 3 RESP n = 29 Gp 4 CTEPH n = 59
Demographics and RHC
Age (yrs) 53 ± 17¶, +, §, ƒ 67 ± 9# 74 ± 9# 67 ± 12# 64 ± 14#
mPAP (mmHg) 54 ± 13¶, +, § 40 ± 13#, ƒ 35 ± 8#, ƒ 39 ± 8#, ƒ 49 ± 10¶, +, §
PCWP (mmHg) 11 ± 3+ 11 ± 4+ 21 ± 4#, ¶, §, ƒ 12 ± 4+ 12 ± 5+
mRAP (mmHg) 11 ± 5 9 ± 5+ 14 ± 5¶, § 9 ± 4+ 12 ± 6
CO (L.min) 4.6 ± 1.4+ 5.2 ± 1.6 6.2 ± 1.7#, ƒ 5.3 ± 1.3 4.8 ± 1.5+
CI (L.min.m-2) 2.5 ± 0.7¶, + 3.1 ± 0.7#, ƒ 3.4 ± 0.8#, ƒ 3.0 ± 0.6 2.5 ± 0.7¶, +
PVR (dyn.s.cm-5) 876 ± 439¶, +, § 484 ± 337#, ƒ, + 183 ± 87¶, #, ƒ, 428 ± 206#, ƒ 736 ± 373¶, +, §
CMR
RVEDVI (ml/m2) 119 ± 47 82 ± 27+, ƒ 91 ± 38 96 ± 33 108 ± 41
VMI (ratio) 1.0 ± 0.4¶, +, § 0.6 ± 0.4#, ƒ, + 0.3 ± 0.1#, ƒ, ¶ 0.6 ± 0.2#, ƒ 0.8 ± 3.1¶, +, §
RV mass index (g/m2) 50 ± 19¶, +, § 27 ± 14#, ƒ 22 ± 11#, ƒ 32 ± 11#, ƒ 43 ± 16¶, +, §
Late gadolinium enhancement ratio and % 21/22 (95%)+ 20/28 (77%) 4/15 (27%)#, ƒ 19/20 (95%) 38/39 (97%)+
RVEF (%) 23 ± 15 32 ± 16 ƒ 32 ± 10 ƒ 24 ± 15 21 ± 12¶, +
RVSVI (ml/m2) 26 ± 21 24 ± 14 29 ± 13 22 ± 13 21 ± 11
TAPSE (cm) 1.5 ± 0.5 1.6 ± 0.7 2.0 ± 0.6§, ƒ 1.4 ± 0.7+ 1.2 ± 0.5+
sEI (ratio) 2.2 ± 0.6¶, +, §, ƒ 1.4 ± 0.4# 1.2 ± 0.2#, ƒ 1.3 ± 0.3#, ƒ 1.6 ± 0.5#,+, §
dEI (ratio) 1.5 ± 0.4¶, +, §, ƒ 1.3 ± 0.2# 1.2 ± 0.2# 1.1 ± 0.1# 1.3 ± 0.3#
Average velocity (cm/s) 7.0 ± 3.0 10.0 ± 3.7 ƒ 9.1 ± 3.4 7.4 ± 3.4 5.9 ± 2.5
Retrograde flow (L/min/m2) 0.5 ± 0.3 0.4 ± 0.3 0.5 ± 0.3 0.4 ± 0.2 0.5 ± 0.3
PA relative area change (%) 6 ± 5+ 9 ± 6 13 ± 10#, ƒ 8.2 ± 6.0 6.5 ± 4.0+
Systolic PA area (cm2) 9.4 ± 1.8 9.0 ± 2.1 9.0 ± 2.2 9.1 ± 1.9 9.9 ± 2.2
Diastolic PA area (cm2) 8.9 ± 1.8 8.1 ± 2.1 7.8 ± 2.0 8.2 ± 2.0 9.2 ± 2.0
  1. Mean ± standard deviation presented.
  2. #: P < 0.05 in comparison to group 1, idiopathic pulmonary arterial hypertension (IPAH).
  3. ¶:P < 0.05 in comparison to group 2, pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD).
  4. +: P < 0.05 in comparison to group 3, pulmonary hypertension owing to left heart disease (PH-LHD).
  5. §: P < 0.05 in comparison to group 4, pulmonary hypertension associated with lung disesae (PH-RESP).
  6. ƒ: P < 0.05 in comparison to group 1, chronic thromboembolic pulmonary hypertension (CTEPH).